Audrey Strauss, the United States Attorney for the Southern District of New York, and Jonathan D. Larsen, the Special Agent in Charge of the New York Field Office of the Internal Revenue Service, Criminal Investigation ( IRS-CI ), announced that Christopher Wright, a citizen of the United Kingdom, was extradited today from Spain. Wright is charged with wire fraud and money laundering relating to his role in a telemarketing scheme involving the fraudulent sale of purported carbon credits to victims in the United Kingdom. Wright was arrested in Spain on January 27, 2021 and is the second defendant charged in the case. Wright is expected to be presented on Friday, April 23, 2021, before U.S. Magistrate Judge James L. Cott. Wright s case is assigned to U.S. District Judge Jesse M. Furman.
Inman Connect
The Real Brokerage Inc., the Canada-based holding company of brokerage Real, will be coming to the Nasdaq during the second quarter of 2021, according to a news brief on Thursday. The company already lists common shares on the Canada-based TSX Venture Exchange under the ticker REAX.
The Real Brokerage also offers common shares on the QTC Markets Group (OTCQX) under the ticker REAXF, which will be changed once their Nasdaq application is approved by the U.S. Securities and Exchange Commission (SEC).
“In advance of an anticipated listing on Nasdaq, Real will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission,” the brief read. “The listing of Real’s shares on Nasdaq remains subject to the approval of Nasdaq and the satisfaction of all applicable listing and regulatory requirements, including meeting the necessary share price requirements and the SEC declaring the Form 40-F Registration Statement effective.”
Stem” or the “
Company“) the first multi-state, integrated cultivation and omnichannel technology cannabis company, announced today the closing of its previously announced marketed public offering (the “
Offering“) of units of the Company (the “
Units“). The Offering was led by Canaccord Genuity Corp. (the “
Agent“) on a ‘commercially reasonable efforts’ basis and consisted of the sale of 18,744,019 Units (including 1,471,291 Units pursuant to the partial exercise of the over-allotment option by the Agent) at a price of $0.55 per Unit for aggregate gross proceeds of $10,309,210 (including $809,210.05 pursuant to the partial exercise of the over-allotment option by the Agent).
We apologize, but this video has failed to load.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic .
Protara TherapeuticsApril 23, 2021 GMT
NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. Based on feedback from the FDA, the Company intends to complete confirmatory, large-scale, GMP manufacturing comparability in the second half of 2021 and subsequently initiate a clinical study in pediatric LM patients pending alignment with FDA on study design.
Provided by GlobeNewswire
Apr 23, 2021 11:00 AM UTC
NEW YORK, April 23, 2021 (GLOBE NEWSWIRE) Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced a path forward related to TARA-002 for the treatment of Lymphatic Malformations (LMs), which are rare malformations of the lymphatic vasculature for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. Based on feedback from the FDA, the Company intends to complete confirmatory, large-scale, GMP manufacturing comparability in the second half of 2021 and subsequently initiate a clinical study in pediatric LM patients pending alignment with FDA on study design.